Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Protalix ( (PLX) ) has issued an update.
On November 3, 2025, Protalix BioTherapeutics and Chiesi Global Rare Diseases announced their request for a re-examination of the European Medicines Agency’s negative opinion on the proposed dosing regimen for Elfabrio, a treatment for Fabry disease. The existing marketing authorization for Elfabrio remains in effect while the re-examination is underway, highlighting the companies’ commitment to addressing the needs of the Fabry community.
The most recent analyst rating on (PLX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.
Spark’s Take on PLX Stock
According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.
Protalix’s overall stock score is driven by strong earnings call insights and positive technical indicators. Financial performance shows improvement, though leverage concerns persist. Valuation remains a moderate risk due to a high P/E ratio.
To see Spark’s full report on PLX stock, click here.
More about Protalix
Protalix BioTherapeutics, Inc. is a biopharmaceutical company that focuses on developing and commercializing recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. The company has achieved FDA approval for proteins produced through this system and has partnered with Chiesi Farmaceutici S.p.A. for the global development of its second product, Elfabrio. Protalix’s pipeline includes products targeting established pharmaceutical markets, such as treatments for Gaucher disease and NETs-related diseases.
Average Trading Volume: 818,733
Technical Sentiment Signal: Buy
Current Market Cap: $189M
Learn more about PLX stock on TipRanks’ Stock Analysis page.